



Clinical trial results:

The time to protection and adherence requirements of Raltegravir with or without lamivudine in protection from HIV infection

Summary

EudraCT number	2016-000437-43
Trial protocol	GB
Global end of trial date	27 September 2018

Results information

Result version number	v1 (current)
This version publication date	27 December 2019
First version publication date	27 December 2019
Summary attachment (see zip file)	FINAL STUDY REPORT (R-PrEPClinical Study Report FINAL 06122019.pdf)

Trial information

Trial identification

Sponsor protocol code	JF-007
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03205566
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Guy's & St. Thomas' NHS Foundation Trust
Sponsor organisation address	Great Maze Pond, London, United Kingdom, SE1 9RT
Public contact	Dr Julie Fox, Guy's & St. Thomas' NHS Foundation Trust, 0044 2071882643, julie.fox@kcl.ac.uk
Scientific contact	Dr Julie Fox, Guy's & St. Thomas' NHS Foundation Trust, 0044 2071882643, julie.fox@kcl.ac.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 September 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	27 September 2018
Global end of trial reached?	Yes
Global end of trial date	27 September 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The level of Raltegravir alone or Raltegravir /lamivudine required in the plasma, vagina, rectum and urethra for ex vivo protection from HIV

Protection of trial subjects:

The trial involves all adult participants who have consented to participate. The trial drugs are licensed and used as per the SmPC. Subjects were excluded if they participated in high-risk behaviour for HIV infection. Which is defined as having one of the following within three months before trial day 0 (first dose): had unprotected vaginal or anal sex with a known HIV infected person or a casual partner. engaged in sex work for money or drugs. acquired a bacterial sexually transmitted disease in the past 3 months. having a known HIV positive partner either currently or in the previous six months

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 August 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 38
Worldwide total number of subjects	38
EEA total number of subjects	38

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	38
From 65 to 84 years	0

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details:

Healthy adult volunteers were recruited through information presented in community organisations, hospitals, colleges, other institutions and/or advertisements, including email responses to expressed interest.

Pre-assignment

Screening details:

Male and female healthy volunteers

Period 1

Period 1 title	Whole trial period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm A

Arm description:

Arm A (A 1 A 2 A 3): will start with 7 days Raltegravir 400mg bd and then have a minimum 4 week wash out before then starting 7 days Raltegravir 400mg /lamivudine 150mg bd.

Arm type	Experimental
Investigational medicinal product name	Raltegravir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

800 mg per day for a maximum of 14 days

Investigational medicinal product name	Lamivudine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

300 mg per day for a maximum of 7 days

Arm title	Arm B
------------------	-------

Arm description:

Arm B (B 1 B 2 B 3): will start with 7 days Raltegravir 400mg /lamivudine 150mg bd and then have a minimum 4 week wash out before then starting 7 days Raltegravir 400mg bd.

Arm type	Experimental
Investigational medicinal product name	Raltegravir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

800 mg per day for a maximum of 14 days

Investigational medicinal product name	Lamivudine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

300 mg per day for a maximum of 7 days

Number of subjects in period 1	Arm A	Arm B
Started	19	19
Completed	18	18
Not completed	1	1
Protocol deviation	1	1

Baseline characteristics

Reporting groups

Reporting group title	Whole trial period
-----------------------	--------------------

Reporting group description: -

Reporting group values	Whole trial period	Total	
Number of subjects	38	38	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	38	38	
From 65-84 years	0	0	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	19	19	
Male	19	19	

End points

End points reporting groups

Reporting group title	Arm A
Reporting group description: Arm A (A 1 A 2 A 3): will start with 7 days Raltegravir 400mg bd and then have a minimum 4 week wash out before then starting 7 days Raltegravir 400mg /lamivudine 150mg bd.	
Reporting group title	Arm B
Reporting group description: Arm B (B 1 B 2 B 3): will start with 7 days Raltegravir 400mg /lamivudine 150mg bd and then have a minimum 4 week wash out before then starting 7 days Raltegravir 400mg bd.	

Primary: Primary Endpoint

End point title	Primary Endpoint ^[1]
End point description:	
End point type	Primary
End point timeframe: Day 0 to day 12 after initiation of IMP.	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Please see attached study report	

End point values	Arm A	Arm B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	18		
Units: Ex vivo HIV protection	18	18		

Attachments (see zip file)	FINAL STUDY REPORT/R-PrEPClinical Study Report FINAL
-----------------------------------	--

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events will be recorded from baseline to 1 day post last dose of IMP.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

Reporting groups

Reporting group title	Whole Study
-----------------------	-------------

Reporting group description: -

Serious adverse events	Whole Study		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 38 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Whole Study		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	27 / 38 (71.05%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Haemorrhoids			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
cyst perianal			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Vascular disorders			
Vaginal spotting			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
General disorders and administration site conditions			

Fatigue			
subjects affected / exposed	3 / 38 (7.89%)		
occurrences (all)	3		
Dehydration			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Rectal pain			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Unwell			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Respiratory, thoracic and mediastinal disorders			
Nose bleed			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Runny nose			
subjects affected / exposed	4 / 38 (10.53%)		
occurrences (all)	4		
Cold			
subjects affected / exposed	3 / 38 (7.89%)		
occurrences (all)	3		
Cough			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Sore throat			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Psychiatric disorders			
Vivid dreams			
subjects affected / exposed	3 / 38 (7.89%)		
occurrences (all)	5		
Sleep disturbance			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Investigations			

Rectal haemorrhage subjects affected / exposed occurrences (all)	1 / 38 (2.63%) 1		
Injury, poisoning and procedural complications Overdose subjects affected / exposed occurrences (all)	1 / 38 (2.63%) 1		
Nervous system disorders Headache subjects affected / exposed occurrences (all) Light headed subjects affected / exposed occurrences (all)	3 / 38 (7.89%) 3 1 / 38 (2.63%) 1		
Blood and lymphatic system disorders Swollen gland subjects affected / exposed occurrences (all) Lump on neck subjects affected / exposed occurrences (all) Abnormal liver function test subjects affected / exposed occurrences (all)	2 / 38 (5.26%) 2 1 / 38 (2.63%) 1 1 / 38 (2.63%) 1		
Gastrointestinal disorders Loose stool subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Tooth impacted	1 / 38 (2.63%) 1 3 / 38 (7.89%) 5 1 / 38 (2.63%) 1		

subjects affected / exposed occurrences (all)	1 / 38 (2.63%) 1		
Skin and subcutaneous tissue disorders Folliculitis subjects affected / exposed occurrences (all)	1 / 38 (2.63%) 1		
Musculoskeletal and connective tissue disorders Painful left toe subjects affected / exposed occurrences (all)	1 / 38 (2.63%) 1		
Infections and infestations			
Viral infection subjects affected / exposed occurrences (all)	1 / 38 (2.63%) 1		
Tonsillitis subjects affected / exposed occurrences (all)	2 / 38 (5.26%) 2		
Pyrexia subjects affected / exposed occurrences (all)	1 / 38 (2.63%) 1		

Additional description: Viral illness with abdominal pain, vomiting, nausea, fever

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported